Literature DB >> 679439

The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholamine infusion in man.

S Simonsen, J K Kjekshus.   

Abstract

The effect of myocardial uptake of free fatty acids (FFAu) on myocardial oxygen consumption (MVO2) in relation to increased heart rate and inotropic stimulation was determined in patients with coronary artery disease. Submaximal atrial pacing and isoproterenol stimulation increased MVO2 by 66% and 142%, respectively, at similar heart rates. Inhibition of lipolysis with beta-pyridyl carbinol almost abolished FFAu and reduced MVO2 significantly. Increased heart rate contributed 47% and FFAu 50% of the raised MVO2 attributed to inotropic stimulation was 30%. Augmentation of FFAu by triglyceride/heparin infusion increased MVO2 significantly above control levels, both during pacing and isoproterenol infusion. We conclude that MVO2 is closely correlated to FFAu, catecholamines sensitize the heart to FFA, and increased FFAu account for a major part of the increased MVO2 during catecholamine stimulation. The importance of reducing heart rate and lipolysis to reduce myocardial oxygen requirements is emphasized.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 679439     DOI: 10.1161/01.cir.58.3.484

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

Review 1.  Metabolic therapy for heart disease: impact of trimetazidine.

Authors:  Hani N Sabbah; William C Stanley
Journal:  Heart Fail Rev       Date:  2005-12       Impact factor: 4.214

Review 2.  Modulating fatty acid oxidation in heart failure.

Authors:  Vincenzo Lionetti; William C Stanley; Fabio A Recchia
Journal:  Cardiovasc Res       Date:  2011-02-02       Impact factor: 10.787

3.  Beta2-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men.

Authors:  Johan Onslev; Glenn Jacobson; Christian Narkowicz; Vibeke Backer; Anders Kalsen; Michael Kreiberg; Søren Jessen; Jens Bangsbo; Morten Hostrup
Journal:  Eur J Appl Physiol       Date:  2017-07-12       Impact factor: 3.078

4.  Effect of acute postinfusion lipemia and free fatty acids on myocardial contractility: assessment with radionuclide ventriculography.

Authors:  L Ackerman; M L Freeman; I Pacold; W E Barnes; B Johnson; R W Reid; H S Loeb; E Kaplan
Journal:  Eur J Nucl Med       Date:  1986

5.  Effects of cardioselective and non-selective beta-adrenoceptor blockade on glycogenolysis, lipolysis and growth hormone secretion.

Authors:  S Raptis
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  Effects of cardioselective and non-cardioselective beta-blockade on adrenaline-induced metabolic and cardiovascular responses in man.

Authors:  S Raptis; J Rosenthal; D Welzel; S Moulopoulos
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

7.  Assessment of metabolic phenotypes in patients with non-ischemic dilated cardiomyopathy undergoing cardiac resynchronization therapy.

Authors:  Sebastian Obrzut; Jay Tiongson; Neema Jamshidi; Huy Minh Phan; Carl Hoh; Ulrika Birgersdotter-Green
Journal:  J Cardiovasc Transl Res       Date:  2010-09-15       Impact factor: 4.132

8.  Heparin, free fatty acids and an increased metabolic demand for oxygen.

Authors:  R T Jung; P S Shetty; W P James
Journal:  Postgrad Med J       Date:  1980-05       Impact factor: 2.401

9.  Effect of heparin on plasma free fatty acid concentrations after acute myocardial infarction.

Authors:  R A Riemersma; R Logan; D C Russell; H J Smith; J Simpson; M F Oliver
Journal:  Br Heart J       Date:  1982-08

10.  Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.

Authors:  Knut Mai; Janin Andres; Katrin Biedasek; Jessica Weicht; Thomas Bobbert; Markus Sabath; Sabine Meinus; Franziska Reinecke; Matthias Möhlig; Martin O Weickert; Markus Clemenz; Andreas F H Pfeiffer; Ulrich Kintscher; Simone Spuler; Joachim Spranger
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.